Integrated digital systems are increasingly becoming part of the medication safety infrastructure, with new evidence suggesting that combining clinical decision support, reminders and other tools can improve safety processes in primary care.

A systematic review and meta-analysis of 74 randomised controlled trials conducted between 2002 and 2025 found that digital interventions were associated with a 46% greater likelihood of improvement in medication safety process measures compared with usual care. Thirteen of the studies included in the review were conducted in the UK or Ireland. The findings, reported by The Pharmaceutical Journal, were published in BMC Medicine and funded through the UK's National Institute for Health and Care Research.

Clinical decision support systems were the most frequently identified intervention, appearing in 59 of the studies, followed by reminders, audit and feedback, and patient-facing components. The researchers found that systems combining multiple components were more effective than single-component interventions, suggesting that medication safety depends increasingly on how digital tools work together rather than on individual technologies operating in isolation.

For pharmaceutical organisations, the findings have implications beyond prescribing software. Medication safety sits across the wider medicines lifecycle, from product selection and prescribing through to monitoring and patient use. Digital systems capable of identifying potentially inappropriate prescribing or supporting clinical decision-making can provide an additional layer of oversight, while also generating data that can inform quality improvement and medicines management. The review identified digital interventions detecting inappropriate prescribing in 25 instances and medication errors in two.

However, the evidence also highlights the operational challenges associated with digital adoption. More than 40% of the studies reported implementation barriers, including difficulties integrating technologies into existing workflows, limited time and resources, and alert fatigue. The NIHR highlighted that excessive alerts and poorly integrated software can disrupt clinical consultations, demonstrating that technology designed to improve safety can introduce new risks when implementation is not carefully managed. The Royal College of Pharmacy similarly emphasised the importance of interoperability, workforce capacity, training and professional judgement when implementing digital tools.

For the sector, the lesson is clear: digital medication safety depends less on deploying individual technologies than on integrating them effectively into clinical workflows. As pharmaceutical and healthcare organisations continue to adopt more connected systems, interoperability, appropriate training, human oversight and careful management of digital alerts will be critical to ensuring technology strengthens rather than complicates safe medicines use.

Source: The Pharmaceutical Journal / BMC Medicine / National Institute for Health and Care Research (NIHR) / Royal College of Pharmacy